Scroll Down

  • Home

  • >
  • Neurodegenerative

  • >
  • Heuron AgingCare Suite™

  • >
  • Heuron IPD

Heuron IPD

Assists in the diagnosis of Parkinson’s disease
by analyzing the nigrosome area on
brain MRI.
MFDS Approved CE Marked

Heuron IPD Brochure

  • MRI Analysis

  • Assessment in the
    asymptomatic stage

  • High Sensitivity
    and Specificity

Workflow Improvement

Detects early signs of Parkinson's disease through the analysis of dopaminergic neuron damage in the nigrosome area on brain MRI.

Supported Features

Detects and visualizes the nigrosome area on Susceptibility Map-Weighted Imaging (SMWI) to analyze the presence or absence of degeneration of dopaminergic neurons.

Accuracy of Conventional
PET Scans 1

  • 93.20%

    Sensitivity
  • 85.70%

    Specificity

Accuracy of
Heuron IPD 2

  • 94.30%

    Sensitivity
  • 91.67%

    Specificity

Validated Performance

Supports the diagnosis with higher sensitivity and specificity than conventional PET scans.

*Source:
1. Clinical usefulness of 18F FP-CIT PET/CT in suspicious early Parkinson’s disease with comparative effectiveness research, NECA, 2015 2. Clinical Study involving 10 institutions, 2020

Heuron IPD

Parkinson’s Disease Diagnosis-Aid

Experience the product's features firsthand from your screen.

L
R

1 / 2

Want to learn more about Heuron IPD?
Explore more with our demo.

TOP